학술논문

Brief Report
Document Type
article
Source
JAIDS Journal of Acquired Immune Deficiency Syndromes. 72(2)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
HIV/AIDS
Vaccine Related
Clinical Research
Vaccine Related (AIDS)
Immunization
Infectious Diseases
Prevention
Aetiology
2.1 Biological and endogenous factors
Infection
Good Health and Well Being
AIDS Vaccines
CD8-Positive T-Lymphocytes
Case-Control Studies
Chemoprevention
Cross-Sectional Studies
HIV Envelope Protein gp120
HIV Infections
HIV-1
Humans
Lymphocyte Activation
Treatment Outcome
HESN
polyfunctionality
T cell
CD8(+)
vaccine
Clinical Sciences
Public Health and Health Services
Virology
Clinical sciences
Epidemiology
Public health
Language
Abstract
Association of HIV-1-specific T-cell responses to infection risk in seronegative individuals is controversial. We quantified and phenotypically characterized gp120-specific T-cell responses in HIV-1 exposed, but uninfected subjects enrolled in the global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial. IFNγ ELISpot responses were detected in 24% of subjects irrespective of infection outcome. HIV-1 gp120 envelope-specific T-cell responses were more uniformly IFN-γ+TNF-α+Mip-1β+ in persistently seronegative subjects relative to subjects who later seroconverted (median frequency of 76.5% and 66.5%, respectively). IFNγ responses targeted the V2 loop for subjects who remained seronegative. HIV-1 gp120 envelope V2 loop-specific CD8 T-cell responses may help to protect against HIV-1 acquisition.